-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of the ADCC platform?
Author:
InnoModels
Release time:
2024-05-24
In the field of biomedicine, research targeting tumor immunotherapy has always been at the forefront of scientists' continuous exploration and breakthroughs. Among them, antibody-dependent cytotoxicity (ADCC), as a key process in natural immune response, has high research value and clinical application potential. With its unique ADCC platform, InnoModels Biotechnology provides powerful and comprehensive support for tumor immunotherapy research.
InnoModels' ADCC platform is highly regarded for its precision, efficiency and clinical relevance. By simulating the ADCC process in the human body, the platform is able to deeply explore the interaction mechanism between antibodies and tumor cells, thus providing powerful support for the development of tumor therapeutic drugs.
First of all, the InnoModels Biotechnology ADCC platform shows great flexibility in the selection of cell sources. The platform can either use tumor cell lines for extensive research and testing, or select primary tumor cells for more realistic simulation experiments. This diversified cell source not only meets the needs of researchers for different experimental conditions, but also improves the reliability and accuracy of experimental results.

Secondly, InnoModels Biotechnology ADCC platform has high precision and sensitivity in the detection of antibody binding to tumor cells. The platform is able to monitor the binding process of antibodies to tumor cell antigens and the cytotoxic activity of NK cells after activation of Fc receptors in real time through advanced technical means. This precise detection capability enables researchers to gain an in-depth understanding of the details of the ADCC process, which in turn provides key information for optimizing antibody design and improving therapeutic efficacy.
In addition, the InnoModels Biotechnology ADCC platform is highly stable and reproducible. The platform adopts advanced experimental techniques and strict experimental procedures to ensure the stability and reliability of each experimental result. This highly consistent experimental data provides researchers with a reliable reference basis and helps accelerate the development process of tumor immunotherapy drugs.
It is worth mentioning that InnoModels Biotechnology also has a stable domestic platform for humanized mouse models of the immune system (HIS) and a platform for human-derived tumor xenografts (PDX). These platforms, together with the ADCC platform, complement each other and constitute the complete layout of InnoModels Electron's research in the field of tumor immunotherapy. These platforms not only provide researchers with experimental conditions closer to the clinic, but also provide powerful technical support for the development and application of tumor immunotherapy drugs.
In summary, with its precision, high efficiency and closeness to the clinic, InnoModels' ADCC platform has demonstrated strong advantages in the field of tumor immunotherapy research. In the future, with the continuous development and innovation of biopharmaceutical technology, InnoModels Biotechnology will continue to plough into this field and contribute more to the research, development and application of tumor immunotherapy drugs.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd